INSTRUCTIONS

medical drug

 

Sodium adenosine triphosphate-Darnitsa

 

(SODIUM adenosintriphosphate-Darnitsa)

 

composition

 

active ingredient: adenosintriphosphate sodium;

1 ml of solution contains ATP of disodium salt (adenosine triphosphate of disodium salt) 10 mg;

Excipients: sodium hydroxide, water for injection.

 

Dosage form. Injection.

Main physical and chemical properties: transparent colorless or slightly yellowish liquid.

 

Pharmacological group. Cardiac drugs. Adenosine.

ATC code C01E B10.

 

Pharmacological properties.

Pharmacological.

 

Adenosine triphosphate (ATP) is a naturally occurring high energy compound. It is synthesized in almost all tissues of the body through oxidative phosphorylation and in the process of splitting carbohydrates. More synthesized in muscle tissue, where the energy contained in ATP molecules is used in muscle contraction. The energy released by the breakdown of ATP is used in the processes of synthesis, in particular protein, and urea.

 

In the nervous system, ATP molecules act as a neurotransmitter, transmit a signal at the purinergic synapses. At the same time, ATP accompanies acetylcholine and noradrenergic mediation.

 

With the systemic administration of sodium, adenosine triphosphate-Darnitsa exhibits a metabolic, antiarrhythmic effect, improves cerebral and coronary circulation. The antiarrhythmic effect is associated with the suppression of the automatism of the sinus node and the conduction of pulses along Purkinje fibers.

 

Partially blocks calcium channels and facilitates transmembrane movement of potassium ions.

 

Pharmacokinetics.

 

It is not possible to track the kinetics of the parenterally administered ATP drug due to the high voltage of various reactions that occur with the participation of its own ATP. However, it is known that sodium adenosine triphosphate rapidly decomposes at the site of administration to adenosine and phosphate residues, which are later used to synthesize new ATP molecules.

Clinical characteristics.

 

Indications.

 

In the complex treatment of muscular dystrophy and atrophy; for stopping paroxysms of ventricular tachycardia; with spasms of peripheral vessels (intermittent claudication, Raynaud's disease, thromboangiitis obliterans).

With central, peripheral and mixed forms of hereditary retinal pigment degeneration.

 

Contraindications.

 

Hypersensitivity to the components of the drug, acute myocardial infarction, arterial hypotension, severe forms of bradyarrhythmia, AV-II-III degree blockade, decompensated stage of heart failure, cardiogenic shock and other types of shocks, QT prolongation syndrome, hemorrhagic stroke, hyperkalemia, hypermagnemia; lung diseases, chronic obstructive pulmonary diseases (for example, bronchial asthma); period of pregnancy and lactation, child age. It can not be administered simultaneously with cardiac glycosides in large doses.

 

Special security measures.

 

The introduction of the drug should be carried out only in the hospital, under observation, while monitoring heart function, slowly, and then measure blood pressure.

 

Interaction with other drugs and other types of interactions.

 

When taken simultaneously with potassium-sparing diuretics, potassium preparations and ACE inhibitors, the risk of developing hyperkalemia increases, with magnesium preparations - hypermagniemia.

 

The drug can enhance the antianginal effect of beta-blockers, nitrates.

 

When combined with dipyridamole increases the effect of dipyridamole, in particular the vasodilator effect.

 

It turns out some antagonism when combined with the derivatives of purine (caffeine and theophylline).

 

It can not be administered simultaneously with cardiac glycosides in large doses, since the risk of the development of adverse reactions from the cardiovascular system increases.

 

With simultaneous use with xanthinol nicotinate, the effect of sodium adenosine triphosphate is reduced.

 

Carbamazepine may increase the effects of adenosine, leading to the development of a blockade.

 

Features of the application.

 

Gently apply with severe bradycardia (with the exception of severe forms of bradyarrhythmia), sick sinus syndrome, AV degree I blockade, susceptibility to arterial hypotension.

 

With prolonged use, it is necessary to control the level of potassium and magnesium in the blood.

 

Be careful when prescribing for bronchospasm.

 

The drug can not be administered in large doses simultaneously with cardiac glycosides.

 

Limit the use of products that contain caffeine (coffee, tea, drinks with cola).

Use during pregnancy or lactation.

 

Data on the use of the drug during pregnancy or breastfeeding are not available.

The ability to influence the reaction rate when driving vehicles or other mechanisms.

 

During treatment, you should refrain from driving or working with mechanisms that require increased attention.

 

Dosage and administration.

 

Sodium adenosine triphosphate-Darnitsa administered intramuscularly or intravenously.

 

For the treatment of muscular dystrophies, disorders of the peripheral blood circulation, in the first 2-3 days, prescribe 1 ml intramuscularly 1 time per day, in the following days - 1 ml 2 times per day or 2 ml at once 1 time per day. The course of treatment is 30-40 days. If necessary, repeat the course in 1-2 months.

 

In case of hereditary retinal pigment degeneration, inject 5 ml intramuscularly 2 times a day with an interval of 6-8 hours daily for 15 days. If necessary, courses can be repeated at intervals of 8-12 months.

 

To stop supraventricular tachyarrhythmias, inject 1-2 ml for 5-10 seconds (the effect is observed after 20-40 seconds). If necessary, re-enter the same dose in 2-3 minutes.

 

Children.

 

The experience of using the drug in children is absent, so the drug is contraindicated in this age group.

 

Overdose

 

Symptoms: dizziness, hypotension, short-term loss of consciousness, arrhythmia, blockade II and III degrees, asystole, bronchospasm, ventricular disorders, sinus bradycardia and tachycardia. Allergic reactions are also possible.

 

Treatment. Introduction of the drug immediately stop and prescribe cardiotonic agents. SPECIAL. Competitive antagonist antagonists is xanthini (aminophylline, theophylline).

 

Adverse reactions.

 

On the part of the nervous system: headache, dizziness, short-term loss of consciousness, feeling of tightness in the head, phobias.

 

On the part of the organ of vision: blurred vision.

 

On the part of the gastrointestinal tract: nausea, metallic taste in the mouth, increased motility of the gastrointestinal tract (for intravenous administration).

 

Since the cardiovascular system: palpitations, chest discomfort, tachycardia or bradycardia, arterial hypotension, arrhythmia, impaired AV conduction (blockade), asystolia.

On the part of the musculoskeletal system: pain in the arms, back, neck.

 

From the urinary system: increased diuresis.

 

On the part of the respiratory system: shortness of breath, bronchospasm.

 

From the skin and subcutaneous tissue: facial flushing, itching, rash on the skin.

Violations at the injection site: tingling sensation, skin flushing.

 

Allergic reactions: hypersensitivity reactions, allergic dermatitis, urticaria, anaphylactic shock, angioedema.

 

Common disorders: excessive sweating, hyperthermia, sensation of heat.

 

Shelf life. 2 years.

 

Storage conditions.

 

Store in original packaging at a temperature of 2 ° to 8 ° C. Keep out of the reach of children.

 

Incompatibility.

 

The drug should not be administered simultaneously with carbamazepine, dipyridamole, xanthines, antiarrhythmic drugs.

 

Packaging.

 

On 1 ml in an ampoule; 10 ampoules in a box of 5 ampoules in a blister pack; 2 packaged in a pack.

 

Vacation category. On prescription.

 

Manufacturer.

 

CJSC Pharmaceutical Firm Darnitsa.

The location of the manufacturer and its address of the place of business.

Ukraine, 02093, city. Kiev, st. Boryspilska, 13.